High Purity Rimonabant Weight Loss Powders Rimonabant Hydrochloride CAS 158681-13-1
- Κατασκευαστής: Dewael
- Δοκιμασία προϊόν: 99%+
- Εμφάνιση:Λευκή κρυσταλλική σκόνη.
- Τόπο καταγωγής: Κίνα
- Πιστοποίηση: SGS,ISO9001, GMP
- Ελάχιστη ποσότητα παραγγελίας: 10σολ
- λεπτομέρειες συσκευασίας: 1 κιλό/τσάντα αλουμινίου,25kg/drum ή ως απαιτήσεις σας
- Ωρα παράδοσης: Στα πλαίσια 12 ώρες μετά τη λήψη της πληρωμής σας
- Οροι πληρωμής: Δυτική Ένωση, MoneyGram,Bitcoin,Τραπεζική μεταφορά
- Αποστολή: EMS,DHL,Fedex,UPS,TNT και ούτω καθεξής.
- Πολιτική: Re-Shipping Πολιτική
- δυνατότητα εφοδιασμού: 500-600kg/μήνα
High Purity Rimonabant Weight Loss Powders Rimonabant Hydrochloride CAS 158681-13-1
Καθέκαστα:
Rimonabant hydrochloride
όνομα προϊόντος: Rimonabant hydrochloride
Συνώνυμα: RIMONABANT HYDROCHLORIDE;5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-n-1-piperidinyl-1h-pyrazole-3-carboxamide monohydrochloride;ACOMPLIA;ACOMPLIA (RIMONABANT;RIMONABANT HCL;Ρουμίμπαντ(Acomplia);RimonabantConsultedStandard;Acomplia, SR141716
CAS: 158681-13-1
MF: C22H21Cl3N4O.ClH
MW: 500.25
Chemical Properties White to Off-White Crystalline Solid
Usage The first of a new class of selective (Cannabinoid-1 (CB-1) receptor antagonists
Usage A brain cannabinoid receptor (CB1) antagonist. Antiobesity agent.
COA:
|
Όνομα προϊόντος
|
Ρουμίμπαντ
|
|||
|
CAS αριθ.
|
168273-06-1 |
Outer Packing
|
1kg/bag | |
|
Production date
|
May 14th. 2018 |
Διάρκεια ζωής
|
May 13th. 2020 | |
|
Products Standard
|
Enterprise Standard | |||
|
Items of analysis
|
Προσδιορισμός
|
Αποτελέσματα
|
||
| Assay by (HPLC) | 99%-101% | 99.43% | ||
| Characters/appearance | White to off White powder | Συμμορφώνεται | ||
| Odor and taste | Odorless | Συμμορφώνεται | ||
| Αναγνώριση | Positive reaction | Συμμορφώνεται | ||
| Mesh size/sieve analysis | 100% pass 80 mesh | Συμμορφώνεται | ||
| Απώλεια κατά το στέγνωμα | 1% Max | 0.78% | ||
| Water | ≤2.0% | 0.1% | ||
| Υπολείμματα κατά την ανάφλεξη | 01%Max | Συμμορφώνεται | ||
| Single impurity | 0.1% Max | Συμμορφώνεται | ||
| Malting point | 272.25 ºC | Συμμορφώνεται | ||
| Bolling point | 627 .69 ºC | Συμμορφώνεται | ||
| Refractive Index | N20O1.67 | Συμμορφώνεται | ||
| ΡΗ | 50-7.0 | 6.5 | ||
| pK Values | pK. 11.31(Predicted). pK„ 3. 22 (Predicted) | Συμμορφώνεται | ||
| Διαλυτότητα | Soluble in ethanol (-20 mg / ml). DMSO (25 mg / ml) .DMF (-20mg / ml). and water (< 1 mg / ml) | Συμμορφώνεται | ||
| Heavy Metals | NMT 10ppm | Συμμορφώνεται | ||
| Microbiological Control | 78cfu/g | 78cfu/g | ||
| Total Plate Count | 1000 cfu/g Max | Negative | ||
| Fungi | <100/σολ | Negative | ||
| Salmonella | Negative | Negative | ||
| Coll | negative | negative | ||
|
Σύναψη
|
Qualified | |||
Rimonabant Description:
(1). Rimonabant hydrochloride (SR-141716A) is a potent and selective CB1 cannabinoid inverse agonist/antagonist with a Ki of 1.6 nM, minimal affinity for CB2, and and some GPR55 agonist activity. Rimonabant was developed as an anti-obesity drug because of its appetite suppressant activity, but was taken off the market because of side effects of depression and anxiety.
(2). Under development by Sanofi-Aventis, Acomplia (rimonabant) is a selective CB1 endocannabinoid receptor antagonist indicated for the treatment of obesity.
(3). It works by blocking endogenous cannabinoid binding to neuronal CB1 receptors. Activation of these receptors by endoegenous cannabinoids, such as anadamide, increases appetite. It is the most advanced endocannabinoid receptor antagonist in clinical development and offers a novel therapeutic approach to appetite control and weight reduction.
Rimonabant Applications:
(1). Rimonabant has a favorable safety profile and is generally well tolerated. Rimonabant is proving to be a very promising approach for managing two major and preventable risk factors for cardiovascular disease. This review summarizes the available evidence on the clinical efficacy and safety of rimonabant as a potential therapy for obesity and smoking cessation.
(2). Rimonabant hydrochloride also has potential as a treatment for smoking cessation because the endocannabinoid system is involved in the body’s response to tobacco dependence.
———————————————————————————————————————————————————————————————————————————————————————-
Επικοινώνησε τώρα
Κριτικές
Δεν υπάρχουν σχόλια ακόμη.